BSN-DT: A Potential Drug Target and Biomarker (G100132677)

Target Name: BSN-DT

NCBI ID: G100132677

BSN-DT

Other Name(s): BSN divergent transcript | BSN-AS2

BSN-DT: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a critical step in the development of new pharmaceuticals. These targets and biomarkers can provide valuable information about the underlying disease or pathology, as well as serve as targets for drug development. One potential target and biomarker that is currently under investigation is BSN-DT.

BSN-DT: Background

BSN-DT is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer. BSN-DT has also been shown to play a role in the regulation of cell survival and has been identified as a potential drug target.

BSN-DT has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer. It has also been shown to contribute to the development of resistance to chemotherapy in cancer cells.

BSN-DT as a drug target

The potential drug target for BSN-DT is based on its role in the regulation of cell cycle and its ability to promote the growth and survival of cancer cells. Drugs that target BSN-DT have the potential to inhibit its activity and disrupt its regulation of cell cycle. This could lead to the inhibition of cancer cell growth and the disruption of their ability to divide and proliferate.

BSN-DT as a biomarker

In addition to its potential as a drug target, BSN-DT has also been shown to be a potential biomarker for the diagnosis and prognosis of cancer. The regulation of cell cycle is a critical aspect of cancer development, and changes in cell cycle regulation can provide valuable information about the severity and progression of cancer.

BSN-DT has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be a useful biomarker for the diagnosis of cancer, as well as for the evaluation of the effectiveness of cancer treatments.

BSN-DT as a target for cancer treatment

The potential drug target for BSN-DT makes it an attractive target for cancer treatment. Drugs that target BSN-DT have the potential to inhibit its activity and disrupt its regulation of cell cycle, leading to the inhibition of cancer cell growth and the disruption of their ability to divide and proliferate.

BSN-DT has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This makes it a potential target for the treatment of these cancers, as well as for other types of cancer.

BSN-DT as a biomarker for cancer diagnosis and treatment

BSN-DT has also been shown to be a potential biomarker for the diagnosis and treatment of cancer. Its regulation of cell cycle plays a critical role in the development and progression of cancer, and changes in cell cycle regulation can provide valuable information about the severity and progression of cancer.

BSN-DT has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This makes it a potential target for the diagnosis and treatment of these cancers, as well as for other types of cancer.

Conclusion

BSN-DT is a protein that has been shown to play a critical role in the regulation of cell cycle and the development and progression of cancer. Its potential as a drug target and biomarker make it an attractive target for cancer treatment. Further research is needed to fully understand the role of BSN-DT in cancer development and treatment.

Protein Name: BSN Divergent Transcript

The "BSN-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BSN-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets